Science News
from research organizations

Proof-of-concept for host-directed tuberculosis therapy established by researchers

Date:
June 27, 2014
Source:
NIH/National Institute of Allergy and Infectious Diseases
Summary:
A new type of tuberculosis treatment that involves manipulating the body's response to TB bacteria rather than targeting the bacteria themselves -- a concept called host-directed therapy -- has been established by researchers. TB remains a major cause of disability and death worldwide as an estimated 8.6 million people fell ill with TB and 1.3 million people died from the disease in 2012.
Share:
       
FULL STORY

In a new study published in Nature, scientists describe a new type of tuberculosis (TB) treatment that involves manipulating the body's response to TB bacteria rather than targeting the bacteria themselves, a concept called host-directed therapy. TB remains a major cause of disability and death worldwide as an estimated 8.6 million people fell ill with TB and 1.3 million people died from the disease in 2012, according to the World Health Organization. Although TB is curable, adherence to therapy is difficult as treatment requires taking antibiotic drugs for at least six months and sometimes up to two years. Poor adherence to medication and other factors have resulted in drug-resistant strains, and currently no effective TB vaccine exists.

To address the need for alternative interventions, scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, demonstrated proof-of-concept for a host-directed strategy to treat tuberculosis. They found that interleukin-1, a type of protein that regulates the body's immune response to infection, can help protect the body from TB infection. Their studies in cells and in mice and human patients infected with TB bacteria demonstrated that interleukin-1 induces a mediator, prostaglandin E2 (PGE2), that limits the production of type-I interferons, which are associated with increased TB disease severity.

The scientists found that host-directed immunotherapy using PGE2 and zileuton, a clinically-approved drug typically used to treat asthma, prevented death in TB-infected mice. This strategy could be of particular benefit to people infected with drug-resistant TB strains who have limited options for effective antibiotics because the treatment increased bacterial control and limited disease even in the absence of TB chemotherapy. In principle, this approach is compatible with standard antibiotic regimens, according to the authors. In future studies, NIAID scientists will test adjunct host-directed therapies in TB-infected individuals.


Story Source:

The above post is reprinted from materials provided by NIH/National Institute of Allergy and Infectious Diseases. Note: Materials may be edited for content and length.


Journal Reference:

  1. Katrin D. Mayer-Barber, Bruno B. Andrade, Sandra D. Oland, Eduardo P. Amaral, Daniel L. Barber, Jacqueline Gonzales, Steven C. Derrick, Ruiru Shi, Nathella Pavan Kumar, Wang Wei, Xing Yuan, Guolong Zhang, Ying Cai, Subash Babu, Marta Catalfamo, Andres M. Salazar, Laura E. Via, Clifton E. Barry III, Alan Sher. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature, 2014; DOI: 10.1038/nature13489

Cite This Page:

NIH/National Institute of Allergy and Infectious Diseases. "Proof-of-concept for host-directed tuberculosis therapy established by researchers." ScienceDaily. ScienceDaily, 27 June 2014. <www.sciencedaily.com/releases/2014/06/140627095153.htm>.
NIH/National Institute of Allergy and Infectious Diseases. (2014, June 27). Proof-of-concept for host-directed tuberculosis therapy established by researchers. ScienceDaily. Retrieved July 5, 2015 from www.sciencedaily.com/releases/2014/06/140627095153.htm
NIH/National Institute of Allergy and Infectious Diseases. "Proof-of-concept for host-directed tuberculosis therapy established by researchers." ScienceDaily. www.sciencedaily.com/releases/2014/06/140627095153.htm (accessed July 5, 2015).

Share This Page: